Literature DB >> 9444422

Alpha-enolase is a renal-specific antigen associated with kidney involvement in mixed cryoglobulinemia.

A Sabbatini1, M P Dolcher, B Marchini, D Chimenti, S Moscato, F Pratesi, S Bombardieri, P Migliorini.   

Abstract

OBJECTIVE: To study the specificity of antibodies reactive with renal antigens in mixed cryoglobulinemia.
METHODS: Sera from mixed cryoglobulinemia (MC) patients were tested on human kidney extracts by immunoblot. A partially purified renal antigen was subjected to N-terminal sequencing.
RESULTS: Antibodies reactive with a renal antigen of 48 kD were detected in 7 out of 11 patients with MC and renal involvement. N-terminal sequencing of this antigen showed that it was identical with alpha-enolase. This result was confirmed by the reactivity of the renal antigen with a rabbit anti-serum specific for alpha-enolase.
CONCLUSIONS: The results indicate that antibodies specific for alpha-enolase are frequently produced by mixed cryoglobulinemia patients with renal involvement.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444422

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  9 in total

1.  Externalized glycolytic enzymes are novel, conserved, and early biomarkers of apoptosis.

Authors:  David S Ucker; Mohit Raja Jain; Goutham Pattabiraman; Karol Palasiewicz; Raymond B Birge; Hong Li
Journal:  J Biol Chem       Date:  2012-01-18       Impact factor: 5.157

2.  Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN).

Authors:  H Wakui; H Imai; A Komatsuda; A B Miura
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 3.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome.

Authors:  L Musante; G Candiano; M Bruschi; L Santucci; B Carnemolla; P Orecchia; M Giampuzzi; C Zennaro; S Sanna-Cherchi; M Carraro; R Oleggini; G Camussi; F Perfumo; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

5.  Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI.

Authors:  Maurizio Bruschi; Renato Alberto Sinico; Gabriella Moroni; Federico Pratesi; Paola Migliorini; Maricla Galetti; Corrado Murtas; Angela Tincani; Michael Madaio; Antonella Radice; Franco Franceschini; Barbara Trezzi; Laura Bianchi; Agata Giallongo; Rita Gatti; Regina Tardanico; Andrea Scaloni; Chiara D'Ambrosio; Maria Luisa Carnevali; Piergiorgio Messa; Pietro Ravani; Giancarlo Barbano; Beatrice Bianco; Alice Bonanni; Francesco Scolari; Alberto Martini; Giovanni Candiano; Landino Allegri; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

Review 6.  Glomerular antibodies in lupus nephritis.

Authors:  Catherine Hanrotel-Saliou; Isabelle Segalen; Yannick Le Meur; Pierre Youinou; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

Review 7.  The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint?

Authors:  Beatrice Goilav; Chaim Putterman
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 8.  Interaction of aldehydes derived from lipid peroxidation and membrane proteins.

Authors:  Stefania Pizzimenti; Eric Ciamporcero; Martina Daga; Piergiorgio Pettazzoni; Alessia Arcaro; Gianpaolo Cetrangolo; Rosalba Minelli; Chiara Dianzani; Alessio Lepore; Fabrizio Gentile; Giuseppina Barrera
Journal:  Front Physiol       Date:  2013-09-04       Impact factor: 4.566

Review 9.  Mixed cryoglobulinemia.

Authors:  Clodoveo Ferri
Journal:  Orphanet J Rare Dis       Date:  2008-09-16       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.